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elimination of activated T cells pro-
ceeds via activation-induced cell death 
(AICD), a process that is dependent on 
Fas signaling and subsequent apoptosis. 
In the absence of adequately controlled 
AICD, T cells are likely to accumulate. 
In both mice and humans, Fas gene 
mutations leading to defective Fas sig-
naling result in lymphoproliferative 
disorders as a consequence of lympho-
cyte accumulation (Rieux-Laucat et al., 
1995). Because in certain types of CTCL 
(MF, SzS) tumor cells have been demon-
strated to be long-lived, activated CD4+ 
cells, defects in Fas-mediated apoptosis 
have recently been suggested to play a 
role in the accumulation of tumor T cells 
that occurs in each disease.
Defective Fas signaling has been 
implicated in the resistance to apopto-
sis induced by chemotherapeutic drugs. 
Furthermore, the lack of functional Fas 
signaling allows tumor cells to escape 
immune surveillance, facilitating dis-
ease progression. Several mechanisms 
contributing to Fas signaling defects in 
cancer have been described, including 
suppressed Fas expression at mRNA and 
protein levels (Bullani et al., 2002; Petak 
et al., 2003). Epigenetic silencing of the 
Fas gene promoter has been shown to 
be regulated by Ras (Gazin et al., 2007). 
Furthermore, mutations or deletions in 
Fas have been found to cause autoim-
mune lymphoproliferative syndromes 
in both mice and humans (Rieux-Laucat 
et al., 1995). Finally, the Fas signaling 
pathway can be modulated by intracel-
lular apoptosis inhibitors such as cellular 
FLICE-like inhibitory protein and Bcl-2 
family members.
Decreased expression of Fas on 
peripheral blood CD4+ T lymphocytes 
in MF and SzS was first reported in 2000 
(Dereure et al., 2000; Zoi-Toli et al., 
2000). More recently, we (Contassot et 
al., 2008) and others (Braun et al., 2007; 
Wu et al., 2009) have reported that a 
decrease, and sometimes a complete loss, 
of Fas expression is a relatively frequent 
event in lymphocytes from patients with 
SzS. In our cohort of 16 SzS patients, 9 
were resistant to FasL, which in 4 patients 
was caused by a loss of Fas expression. 
In MF, resistance to FasL-induced apop-
tosis has already been attributed to muta-
tions in the Fas gene (Dereure et al., 
2002; Nagasawa et al., 2004) and to the 
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Epigenetic Causes of Apoptosis Resistance 
in Cutaneous T-Cell Lymphomas
Emmanuel Contassot1 and Lars E. French1
In cutaneous T-cell lymphomas (CTCLs) defects in Fas-mediated apoptosis have 
been suggested to be involved in disease pathogenesis. Decreased or absent Fas 
expression has been reported in a significant proportion of CTCL patients, but 
the molecular mechanisms of such impaired Fas expression have hardly been 
investigated to date. In this issue, Jones et al. show that defective Fas expression 
is attributable to positional methylation of the Fas gene.
Journal of Investigative Dermatology (2010) 130, 922–924. doi:10.1038/jid.2009.427
1Department of Dermatology, University Hospital, Zurich, Switzerland
Correspondence: Lars E. French, Department of Dermatology, University Hospital,  
Gloriastrasse 31, 8091 Zurich, Switzerland. E-mail: lars.french@usz.ch
Cutaneous T-cell lymphomas (CTCLs) 
are a heterogeneous group of non-
Hodgkin’s lymphomas characterized 
by the clonal proliferation of skin hom-
ing T cells. The most common CTCLs 
are mycosis fungoides (MF) and Sézary 
syndrome (SzS), an aggressive leukemic 
variant of MF. The tumor cells in MF 
and SzS exhibit a T helper type 2 (Th2) 
cytokine profile that contributes to asso-
ciated immunosuppression. Biologic 
response modifiers such as IFN-α, IFN-γ, 
and IL-12, which stimulate T helper 1 
responses, have significant therapeutic 
effects in SzS.
Appropriate Fas-mediated cell death 
is crucial for T-cell homeostasis. The 
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expression of a nonfunctional Fas splice 
variant (van Doorn et al., 2002) (Table 1). 
Until now, the exact mechanisms lead-
ing to the decrease—or loss—of Fas 
expression on CD4+ tumor cells from SzS 
patients has not been investigated. In this 
issue, Jones et al. show that Fas expres-
sion at both mRNA and protein levels is 
decreased on CD4+ cells in a significant 
proportion (21/47, 45%) of SzS patients 
as compared with CD4+ cells from 
healthy donors. Notably, the authors 
demonstrate that the underexpression of 
Fas is attributable to positional methy-
lation of the Fas CpG island and not to 
functional mutations within the tran-
scribed Fas region.
It is known that cancer cells exhibit 
aberrant gene expression and, in the past 
decade, epigenetics research has revealed 
that, together with histone acetylation, 
DNA hypermethylation of CpG-rich pro-
moter sequences is associated with the 
inactivation of several tumor suppressor 
genes in several types of cancers (Esteller, 
2007). In the human genome, approxi-
mately half of the gene-promoter regions 
contain CpG-rich regions, the so-called 
CpG islands (Bird, 1986; Gardiner-
Garden and Frommer, 1987). The major-
ity of the CpG islands are located in the 
5′ untranslated region and the first exon 
of genes. Such CpG-rich regions are 
prone to hypermethylation. DNA methyl-
ation consists of the addition of a methyl 
group to the carbon 5 position of the 
cytosine ring in the CpG dinucleotide by 
DNA methyltransferase, resulting in the 
formation of methylcytosine (Holliday 
and Grigg, 1993). Although CpG-island 
hypermethylation profiles vary with 
tumor type (Costello et al., 2000), such 
epigenetic alterations play important 
roles in the pathogenesis of cancer. These 
studies have shown not only that genes 
involved in the control of cell growth are 
affected but also that promoter hyper-
methylation affects apoptosis regulator 
genes. Analysis of DNA hypermethyla-
tion is already used in selected instances 
as a marker for the diagnosis of cancer 
and as a surrogate marker for the predic-
tion of responses to chemotherapy.
Therapeutic strategies aiming to 
revert DNA methylation and histone 
acetylation exist. Histone deacetylase 
(HDAC) inhibitors reverse some of the 
aberrant epigenetic alterations associated 
with cancer, resulting in re-expression of 
silenced genes involved in growth arrest, 
terminal differentiation, and/or apopto-
sis in carcinoma cells. Recently, HDAC 
inhibitors (vorinostat and romidepsin) 
have also been evaluated for the treat-
ment of refractory CTCLs. Responses 
rates ranging from 24 to 34% were 
reported for all MF disease stages, and 
similar responses were reported for SzS 
(Olsen et al., 2007; Piekarz et al., 2009). 
The observation that CTCLs can respond 
favorably to HDAC inhibitors strongly 
supports the idea that epigenetic altera-
tions may play an important role in the 
pathogenesis of these malignancies (Batty 
et al., 2009; Piekarz et al., 2009).
Given the apparent importance of 
CpG island methylation in the patho-
genesis of hematological malignancies, 
the use of 5-azacitidine and 5-aza-2′-
deoxycytidine, two hypomethylating 
agents, has also been considered for 
table 1. Genetic and epigenetic alterations of Fas in ctcLs
cause Disease Frequency (%) references
FAS mutations MF 6/44 patients (14) Dereure et al., 2002
MF 3/16 patients (18) Nagasawa et al., 2004




Van Doorn et al., 2002
Promoter hypermethylation SzS 21/47 (45) Jones et al., 2010 
MF, mycosis fungoides; PCLTCL, primary cutaneous large T-cell lymphoma; SzS, Sézary syndrome.
Clinical Implications
•  Defects in apoptosis may play a role in the accumulation of tumor  
T cells in CTCLs (mycosis fungoides and Sézary syndrome).
•  Histone deacetylase inhibitors reverse some of the aberrant 
alterations associated with cancer, resulting in re-expression  
of genes involved in apoptosis.
•  Two histone deacetylase inhibitors (vorinostat and romidepsin) 
appear to have value in treating CTCLs.
hematological malignancies, either alone 
or in combination with HDAC inhibitors. 
The two drugs cited above have been 
shown to have significant activity in 
patients with high-risk myelodysplastic 
syndromes (Fenaux et al., 2007). Studies 
have provided evidence for epigenetic 
instability and promoter methylation in 
CTCLs, leading to the deregulation of 
tumor suppressor genes involved in cell 
cycle control (p15, p16, p73, CHFR), 
DNA repair (MGMT), and apoptosis 
signaling (TMS1, p73) (Scarisbrick et 
al., 2002). Taken together with the data 
reported by Jones et al. in this issue, it 
appears that further investigation of the 
use of demethylating agents in CTCLs, 
including SzS, is warranted.
Recent studies have shown that resto-
ration of Fas expression on tumor cells 
can also be achieved either by the in 
vitro exposure of tumor cells to IFN-α or 
IFN-γ or by Fas gene transfer (Contassot 
et al., 2008; Wu et al., 2009). Such 
approaches could represent a strategy 
for counteracting apoptosis resistance 
in SzS; however, the downregulation 
of Fas expression on SzS CD4+ cells 
is not the only cause of resistance to 
FasL-mediated apoptosis in CTCLs. In 
this context, it has recently been shown 
that the intracellular apoptosis inhibitor 
cFLIP is overexpressed in Fas-expressing 
apoptosis-resistant CD4+ tumor cells in 
CTCLs, thus providing another molecu-
lar mechanism for resistance to death 
receptor-mediated apoptosis (Braun 
et al., 2007; Contassot et al., 2008). 
Furthermore, the observation that certain 
Bcl-2 family members, such as Mcl-1, 
are also overexpressed in CTCLs sug-
gests that they may also contribute to the 
resistance to death receptor-mediated 
apoptosis (Zhang et al., 2003). Thus, 
in CTCLs, tumor T cells may acquire 
resistance to Fas-mediated apoptosis via 
several independent mechanisms.
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The findings reported by Jones et al. 
are of importance when considering the 
optimal therapeutic strategy to initiate 
in a given patient with CTCL. Because 
methylation of the Fas promoter is not 
observed in all patients with SzS, the use 
of hypomethylating drugs may not be 
equally effective in restoring sensitivity 
to Fas-mediated apoptosis in all patients. 
Thus, not only is the existence of potent 
hypomethylating agents important, but 
their use will require a “personalized” 
medical approach in which these agents 
are employed in patients having tumors 
with positional methylation of the Fas 
CpG island.
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How Does Intramolecular Epitope 
Spreading Occur in BPAG2 (BP180)?
Takashi Hashimoto1, Takahiro Hamada1, Teruki Dainichi1, Norito Ishii1, 
Tadashi Karashima1, Takekuni Nakama1 and Shinichiro Yasumoto1
Several studies have suggested that autoantibodies directed against multiple 
epitopes occur via epitope spreading in autoimmune bullous skin diseases. 
However, the precise sequence of events in epitope spreading has not been elu-
cidated for any of the epidermal autoantigens. In this issue, using a transgenic 
mouse model, Di Zenzo et al. report that intramolecular epitope spreading does 
occur for human BPAG2.
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In order to investigate the mechanism 
of epitope spreading for BPAG2 (BP180 
or type XVII collagen), Di Zenzo et al. 
(2010, this issue) performed a sophis-
ticated set of experiments using trans-
genic mice harboring human BPAG2. 
To immunize mice with human BPAG2, 
skin samples from transgenic mice that 
expressed human BPAG2 were grafted 
onto syngeneic mice. Sequential serum 
samples were then obtained from 
the immunized mice, and antibodies 
against human BPAG2 were detected 
by an enzyme-linked immunosorbent 
assay using recombinant proteins for 
four intracellular domains (ICDs) and 
three extracellular domains (ECDs) 
of human BPAG2. Most grafted mice 
with cutaneous t-cell lymphoma. J Clin Oncol 
27:5410–7
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